Over 12 million people in the United States died from all causes between the beginning of January 2020 and August 21, 2023. Over 1.1 million of those deaths were with confirmed or presumed COVID-19.

Vaccine rollout in the United States Finding a safe and effective COVID-19 vaccine was an urgent health priority since the very start of the pandemic. In the United States, the first two vaccines were authorized and recommended for use in December 2020. One has been developed by Massachusetts-based biotech company Moderna, and the number of Moderna COVID-19 vaccines administered in the U.S. was over 250 million. Moderna has also said that its vaccine is effective against the coronavirus variants first identified in the UK and South Africa.

Deaths counts for influenza, pneumonia, and COVID-19 reported to NCHS by week ending date, by state and HHS region, and age group.

Between January and August 2020, there has been approximately 48.2 thousand deaths in England and Wales with COVID-19 as an underlying cause. As illustrated in the table, the number of deaths as a result of COVID-19 are much higher than from either pneumonia or influenza. There has been over three times the number of deaths from COVID-19 than pneumonia and influenza so far in 2020. The overall number of confirmed COVID-19 cases in the UK can be found here. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

As of January 6, 2022, an average of 1,192 people per day have died from COVID-19 in the U.S. since the first case was confirmed in the country on January 20th the year before. On an average day, nearly 8,000 people die from all causes in the United States, based on data from 2019. Based on the latest information, roughly one in seven deaths each day were related to COVID-19 between January 2020 and January 2022. However, there were even days when more than every second death in the U.S. was connected to COVID-19. The daily death toll from the seasonal flu, using preliminary maximum estimates from the 2019-2020 influenza season, stood at an average of around 332 people. We have to keep in mind that a comparison of influenza and COVID-19 is somewhat difficult. COVID-19 cases and deaths are counted continuously since the begin of the pandemic, whereas flue counts are seasonal and often less accurate. Furthermore, during the last two years, COVID-19 more or less 'replaced' the flu, with COVID-19 absorbing potential flu cases. Many countries reported a very weak seasonal flu activity during the COVID-19 pandemic. But it has yet to be seen how the two infectious diseases will develop side by side during the winter season 2021/2022 and in the years to come.

Symptoms and self-isolation COVID-19 and influenza share similar symptoms – a cough, runny nose, and tiredness – and telling the difference between the two can be difficult. If you have minor symptoms, there is no need to seek urgent medical care, but it is recommended that you self-isolate, whereas rules vary from country to country. Additionally, rules depend on someone's vaccination status and infection history. However, if you think you have the disease, a diagnostic test can show if you have an active infection.

Scientists alert to coronavirus mutations The genetic material of the novel coronavirus is RNA, not DNA. Other notable human diseases caused by RNA viruses include SARS, Ebola, and influenza. A continual problem that vaccine developers encounter is that viruses can mutate, and a treatment developed against a certain virus type may not work on a mutated form. The seasonal flu vaccine, for example, is different each year because influenza viruses are frequently mutating, and it is critical that those genetic changes continue to be tracked.

Provisional counts of the number of death occurrences in England and Wales due to coronavirus (COVID-19) and influenza and pneumonia, by age, sex and place of death.

As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had spread to almost every country in the world, and more than 6.86 million people had died after contracting the respiratory virus. Over 1.16 million of these deaths occurred in the United States.

Waves of infections Almost every country and territory worldwide have been affected by the COVID-19 disease. At the end of 2021 the virus was once again circulating at very high rates, even in countries with relatively high vaccination rates such as the United States and Germany. As rates of new infections increased, some countries in Europe, like Germany and Austria, tightened restrictions once again, specifically targeting those who were not yet vaccinated. However, by spring 2022, rates of new infections had decreased in many countries and restrictions were once again lifted.

What are the symptoms of the virus? It can take up to 14 days for symptoms of the illness to start being noticed. The most commonly reported symptoms are a fever and a dry cough, leading to shortness of breath. The early symptoms are similar to other common viruses such as the common cold and flu. These illnesses spread more during cold months, but there is no conclusive evidence to suggest that temperature impacts the spread of the SARS-CoV-2 virus. Medical advice should be sought if you are experiencing any of these symptoms.

Context

Dataset aims to facilitate a state by state comparison of potential risk factors that may heighten Covid 19 transmission rates or deaths. It includes state by state estimates of: covid 19 positives/deaths, flu/pneumonia deaths, major city population densities, available hospital resources, high risk health condition prevalance, population over 60, means of work transportation rates, housing characteristics (ie number of large apartment complexes/seniors living alone), and industry information.

Content

The Data Includes:

1) Covid 19 Outcome Stats:

Covid_Death : Covid Deaths by State

Covid_Positive : Covid Positive Tests by State

2) US Major City Population Density by State: CBSA_Major_City_max_weighted_density

3) KFF Estimates of Total Hospital Beds by State:

Kaiser_Total_Hospital_Beds

4) 2018 Season Flu and Pneumonia Death Stats:

FLUVIEW_TOTAL_PNEUMONIA_DEATHS_Season_2018

FLUVIEW_TOTAL_INFLUENZA_DEATHS_Season_2018

5)US Total Rates of Flu Hospitalization by Underlying Condition:

Fluview_US_FLU_Hospitalization_Rate_....

6) State by State BRFSS Prevalance Rates of Conditions Associated with Higher Flu Hospitalization Rates

BRFSS_Diabetes_Prevalance BRFSS_Asthma_Prevalance BRFSS_COPD_Prevalance
BRFSS_Obesity BMI Prevalance BRFSS_Other_Cancer_Prevalance BRFSS_Kidney_Disease_Prevalance BRFSS_Obesity BMI Prevalance BRFSS_2017_High_Cholestoral_Prevalance BRFSS_2017_High_Blood_Pressure_Prevalance Census_Population_Over_60

7)State by state breakdown of Means of Work Transpotation:

COMMUTE_Census_Worker_Public_Transportation_Rate

8) State by state breakdown of Housing Characteristics

9) State by State breakdown of Industry Information

Acknowledgements

Links to data sources:

https://worldpopulationreview.com/states/

https://covidtracking.com/data/

https://gis.cdc.gov/GRASP/Fluview/FluHospRates.html https://www.kff.org/health-costs/issue-brief/state-data-and-policy-actions-to-address-coronavirus/#stateleveldata

https://data.census.gov/cedsci/table?q=United%20States&tid=ACSDP1Y2018.DP05&hidePreview=true&vintage=2018&layer=VT_2018_040_00_PY_D1&cid=S0103_C01_001E

Census Tables: ACSST1Y2018.S1811 ACSST1Y2018.S0102 ACSST1Y2018.S2403 ACSST1Y2018.S2501 ACSST1Y2018.S2504

https://www.census.gov/library/visualizations/2012/dec/c2010sr-01-density.html

https://gis.cdc.gov/grasp/fluview/mortality.html

Inspiration

I hope to show the existence of correlations that warrant a deeper county by county analysis to identify areas of increased risk requiring increased resource allocation or increased attention to preventative measures.

This dataset is a per-state amalgamation of demographic, public health and other relevant predictors for COVID-19.

Deaths, Infections and Tests by State

The COVID Tracking Project: https://covidtracking.com/data/api

Used positive, death and totalTestResults from the API for, respectively, Infected, Deaths and Tested in this dataset. Please read the documentation of the API for more context on those columns

Predictor Data and Sources

Population (2020)

Density is people per meter squared https://worldpopulationreview.com/states/

ICU Beds and Age 60+

https://khn.org/news/as-coronavirus-spreads-widely-millions-of-older-americans-live-in-counties-with-no-icu-beds/

GDP

https://worldpopulationreview.com/states/gdp-by-state/

Income per capita (2018)

https://worldpopulationreview.com/states/per-capita-income-by-state/

Gini

https://en.wikipedia.org/wiki/List_of_U.S._states_by_Gini_coefficient

Unemployment (2020)

Rates from Feb 2020 and are percentage of labor force
https://www.bls.gov/web/laus/laumstrk.htm

Sex (2017)

Ratio is Male / Female
https://www.kff.org/other/state-indicator/distribution-by-gender/

Smoking Percentage (2020)

https://worldpopulationreview.com/states/smoking-rates-by-state/

Influenza and Pneumonia Death Rate (2018)

Death rate per 100,000 people
https://www.cdc.gov/nchs/pressroom/sosmap/flu_pneumonia_mortality/flu_pneumonia.htm

Chronic Lower Respiratory Disease Death Rate (2018)

Death rate per 100,000 people
https://www.cdc.gov/nchs/pressroom/sosmap/lung_disease_mortality/lung_disease.htm

Active Physicians (2019)

https://www.kff.org/other/state-indicator/total-active-physicians/

Hospitals (2018)

https://www.kff.org/other/state-indicator/total-hospitals

Health spending per capita

Includes spending for all health care services and products by state of residence. Hospital spending is included and reflects the total net revenue. Costs such as insurance, administration, research, and construction expenses are not included.
https://www.kff.org/other/state-indicator/avg-annual-growth-per-capita/

Pollution (2019)

Pollution: Average exposure of the general public to particulate matter of 2.5 microns or less (PM2.5) measured in micrograms per cubic meter (3-year estimate)
https://www.americashealthrankings.org/explore/annual/measure/air/state/ALL

Medium and Large Airports

For each state, number of medium and large airports https://en.wikipedia.org/wiki/List_of_the_busiest_airports_in_the_United_States

Temperature (2019)

Note that FL was incorrect in the table, but is corrected in the Hottest States paragraph
https://worldpopulationreview.com/states/average-temperatures-by-state/
District of Columbia temperature computed as the average of Maryland and Virginia

Urbanization (2010)

Urbanization as a percentage of the population https://www.icip.iastate.edu/tables/population/urban-pct-states

Age Groups (2018)

https://www.kff.org/other/state-indicator/distribution-by-age/

School Closure Dates

Schools that haven't closed are marked NaN https://www.edweek.org/ew/section/multimedia/map-coronavirus-and-school-closures.html

Note that some datasets above did not contain data for District of Columbia, this missing data was found via Google searches manually entered.

This dataset represents preliminary estimates of cumulative U.S. COVID-19 disease burden for the 2024-2025 period, including illnesses, outpatient visits, hospitalizations, and deaths. The weekly COVID-19-associated burden estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The data come from the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), a surveillance platform that captures data from hospitals that serve about 10% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of COVID-19 -associated burden that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent COVID-19-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

References

1. Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369 
2. Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486
3. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 
4. Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.
5. Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm 
6. Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  
7. Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.
8. https://www.cdc.gov/covid/php/covid-net/index.html">COVID-NET | COVID-19 | CDC 
9. https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html 
10. https://academic.oup.com/pnasnexus/article/1/3/pgac079/6604394?login=false">Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)
11. Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

Worries about the impact of COVID-19 on pregnant mothers and their offspring are widespread. Data from New York City in 2020 and Philadelphia in 1918 were used to compare to COVID-19 mortality rates versus Spanish Flu mortality rates by age and gender. The data show that COVID-19 mortality rates have been much higher for individuals over 60 compared to the Spanish Flu, which had much higher mortality rates for people between the ages of 20-40. Data on COVID-19 death counts for New York City from Centers for Disease Control and Prevention (2020) combined with population estimates for 2017 from New York State Department of Health (2017). Data on Spanish Influenza from Rogers (1920). Data is accessible to people who have an OPEN ICPSR account.

This statistic shows the estimated number of people who died in the United States during influenza pandemics. During the Spanish flu from 1918 to 1919 around 675,000 people in the U.S. were estimated to have died. More recently, around 12,469 people died from the swine flu or H1N1 pandemic in 2009.

Data is from the California Department of Public Health (CDPH) Respiratory Virus Weekly Report.

The report is updated each Friday.

Laboratory surveillance data: California laboratories report SARS-CoV-2 test results to CDPH through electronic laboratory reporting. Los Angeles County SARS-CoV-2 lab data has a 7-day reporting lag. Test positivity is calculated using SARS-CoV-2 lab tests that has a specimen collection date reported during a given week.

Laboratory surveillance for influenza, respiratory syncytial virus (RSV), and other respiratory viruses (parainfluenza types 1-4, human metapneumovirus, non-SARS-CoV-2 coronaviruses, adenovirus, enterovirus/rhinovirus) involves the use of data from clinical sentinel laboratories (hospital, academic or private) located throughout California. Specimens for testing are collected from patients in healthcare settings and do not reflect all testing for influenza, respiratory syncytial virus, and other respiratory viruses in California. These laboratories report the number of laboratory-confirmed influenza, respiratory syncytial virus, and other respiratory virus detections and isolations, and the total number of specimens tested by virus type on a weekly basis.

Test positivity for a given week is calculated by dividing the number of positive COVID-19, influenza, RSV, or other respiratory virus results by the total number of specimens tested for that virus. Weekly laboratory surveillance data are defined as Sunday through Saturday.

Hospitalization data: Data on COVID-19 and influenza hospital admissions are from Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN) Hospitalization dataset. The requirement to report COVID-19 and influenza-associated hospitalizations was effective November 1, 2024. CDPH pulls NHSN data from the CDC on the Wednesday prior to the publication of the report. Results may differ depending on which day data are pulled. Admission rates are calculated using population estimates from the P-3: Complete State and County Projections Dataset provided by the State of California Department of Finance (https://dof.ca.gov/forecasting/demographics/projections/). Reported weekly admission rates for the entire season use the population estimates for the year the season started. For more information on NHSN data including the protocol and data collection information, see the CDC NHSN webpage (https://www.cdc.gov/nhsn/index.html).

CDPH collaborates with Northern California Kaiser Permanente (NCKP) to monitor trends in RSV admissions. The percentage of RSV admissions is calculated by dividing the number of RSV-related admissions by the total number of admissions during the same period. Admissions for pregnancy, labor and delivery, birth, and outpatient procedures are not included in total number of admissions. These admissions serve as a proxy for RSV activity and do not necessarily represent laboratory confirmed hospitalizations for RSV infections; NCKP members are not representative of all Californians.

Weekly hospitalization data are defined as Sunday through Saturday.

Death certificate data: CDPH receives weekly year-to-date dynamic data on deaths occurring in California from the CDPH Center for Health Statistics and Informatics. These data are limited to deaths occurring among California residents and are analyzed to identify influenza, respiratory syncytial virus, and COVID-19-coded deaths. These deaths are not necessarily laboratory-confirmed and are an underestimate of all influenza, respiratory syncytial virus, and COVID-19-associated deaths in California. Weekly death data are defined as Sunday through Saturday.

Wastewater data: This dataset represents statewide weekly SARS-CoV-2 wastewater summary values. SARS-CoV-2 wastewater concentrations from all sites in California are combined into a single, statewide, unit-less summary value for each week, using a method for data transformation and aggregation developed by the CDC National Wastewater Surveillance System (NWSS). Please see the CDC NWSS data methods page for a description of how these summary values are calculated. Weekly wastewater data are defined as Sunday through Saturday.

BackgroundCOVID-19 and influenza can both lead to acute kidney injury (AKI) as a common complication. However, no meta-analysis has been conducted to directly compare the incidence of AKI between hospitalized patients with COVID-19 and influenza. The objective of our study aims to investigate the incidence and outcomes of AKI among hospitalized patients between these two groups.Materials and methodsA systematic search of PubMed, Embase, and Cochrane databases was conducted from December 2019 to August 2023 to identify studies examining AKI and clinical outcomes among hospitalized patients with COVID-19 and influenza. The primary outcome of interest was the incidence of AKI, while secondary outcomes included in-hospital mortality, recovery from AKI, hospital and ICU stay duration. The quality of evidence was evaluated using Cochrane and GRADE methods.ResultsTwelve retrospective cohort studies, involving 17,618 hospitalized patients with COVID-19 and influenza, were analyzed. COVID-19 patients showed higher AKI incidence (29.37% vs. 20.98%, OR: 1.67, 95% CI 1.56–1.80, p 

The Chicago Department of Public Health (CDPH) receives weekly deidentified provisional death certificate data for all deaths that occur in Chicago, which can include both Chicago and non-Chicago residents from the Illinois Department of Public Health (IDPH) Illinois Vital Records System (IVRS). CDPH scans for keywords to identify deaths with COVID-19, influenza, or respiratory syncytial virus (RSV) listed as an immediate cause of death, contributing factor, or other significant condition. The percentage of all reported deaths that are attributed to COVID-19, influenza, or RSV is calculated as the number of deaths for each respective disease divided by the number of deaths from all causes, multiplied by 100. This dataset reflects death certificates that have been submitted to IVRS at the time of transmission to CDPH each week – data from previous weeks are not updated with any new submissions to IVRS. As such, estimates in this dataset may differ from those reported through other sources. This dataset can be used to understand trends in COVID-19, influenza, and RSV mortality in Chicago but does not reflect official death statistics. Source: Provisional deaths from the Illinois Department of Public Health Illinois Vital Records System.

Extracorporeal membrane oxygenation (ECMO) has been used extensively for H1N1 influenza and coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) to improve gas exchange and quickly correct hypoxemia and hypercapnia. This systematic review summarized the evidence on ECMO for the treatment of COVID-19 and influenza-associated ARDS. This is a systematic review and meta-analysis of studies to compare the efficacy and safety of ECMO with conventional mechanical ventilation in adults with COVID-19 and influenza-associated ARDS. The study performed a structured search on PubMed, Embase, Web of Science, Scopus and The Cochrane Library. The primary outcome was hospital mortality. The study included 15 observational studies with 5239 patients with COVID-19 and influenza-associated ARDS. The use of ECMO significantly reduced in-hospital mortality in COVID-19-associated ARDS (OR = 0.40; 95% CI = 0.27–0.58; P 

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.